Tokyo, June 24 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062024) titled 'An in silico study comparing dose distributions between carbon ion radiotherapy and stereotactic body radiotherapy for hepatocellular carcinoma' on June 24.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - National Institutes for Quantum Science and Technology (QST)
Condition:
Condition - hepatocellular carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to identify clinical conditions in which carbon ion radiotherapy is advantageous by generating dose distributions for stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (tumor diameter under 5 cm) treated with carbon ion radiotherapy at our institution, and comparing them with the dose distributions of carbon ion radiotherapy, taking into account tumor size and location.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with hepatocellular carcinoma who underwent carbon-ion radiotherapy between January 2025 and December 2025
Patients with a maximum tumor diameter of <5 cm before treatment
Key exclusion criteria - Patients who opted out of the use of their information for this study
Target Size - 40
Recruitment Status:
Recruitment status - Enrolling by invitation
Date of protocol fixation - 2026 Year 06 Month 04 Day
Date of IRB - 2026 Year 06 Month 10 Day
Anticipated trial start date - 2026 Year 06 Month 24 Day
Last follow-up date - 2029 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070973
Disclaimer: Curated by HT Syndication.
